My Profile

Search abstracts

Lewis Sheiner

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

PAGE 27 (2018) Abstr 8689 []

PDF poster/presentation:
Click to open Click to open

Poster: Methodology - New Modelling Approaches

II-03 Elvira Erhardt Bayesian knowledge integration for an in vitro–in vivo correlation (IVIVC) model

Elvira M. Erhardt (1), Moreno Ursino (2), Tom Jacobs (3), Jeike Biewenga (3), Mauro Gasparini (1)

(1) Politecnico di Torino, Turin, Italy, (2) INSERM, University Paris 5 and 6, France (3) Janssen Pharmaceutica NV, Beerse, Belgium


In vitro–in vivo correlation (IVIVC) methods play a key role in the drug development and optimization of formulations. An IVIVC is defined by the Food and Drug Administration as the mathematical relationship between the in vitro characteristics of a dosage form and its in vivo response. This tool can act as a surrogate for bioequivalence or bioavailability testing in human subjects, thus support biowaivers and thereby reduce cost and duration of the optimization process [1]. However, most of the current IVIVC models entail complex and potentially unstable mathematical deconvolution operations and are assessed applying purely frequentist methods, such as linear regression, on averaged data [2]. We suggest a new predictive model for the pharmacokinetic (PK) data of a controlled release (CR) formulation through combination of an in vitro model of the drug release with an in vivo immediate release (IR) model. Simultaneously, we account for the uncertainty in the parameter estimates.


The proposed 3-step IVIVC approach includes (a) a frequentist nonlinear mixed effects model [3] for the in vitro release data; (b) a frequentist population PK compartment model for the in vivo IR data (fitted using the NLMIXR package [4] in R); and (c) a system of ordinal differential equations containing the submodels (a) and (b), which approximates and predicts the in vivo blood concentration-time, using in vivo controlled release data. The innovation consists of splitting the parameter space between submodels (a) and (b) versus (c) and, subsequently, accounting for the uncertainty around these parameters via a Bayesian framework (in the software STAN [5]). That is, estimates from the first two frequentist submodels serve as priors for the Bayesian hierarchical third submodel; the prior standard deviations account for the variability around the previously estimated parameters [6]. We demonstrate the application of the method using the study data of a transdermal patch, in (a) and (c), and of an intravenous infusion, in (b), as an example.


The in vitro release was well-approximated by a Weibull input-function; a three-compartment model described the IR concentration data of the population PK adequately. The combined ODE converged with a reasonable run-time and the predicted drug concentration-time profiles are comparable with the in vivo observations. Thus, the developed IVIVC model led to a satisfactory estimation of the case study.


The Bayesian method explained ensures a natural integration of knowledge from one source of information into the other, from in vitro to in vivo, making the best use out of our prior information and proper modelling of uncertainty. Many authors before us used plug-in estimates from the first stage of PK modelling without accounting for their uncertainty; we believe this may introduce an undue over-confidence in the model. Our generally applicable two-stage Bayesian approach is combining the benefits of one- and two-stage frequentist models. Therefore, it is an improvement of the current IVIVC methodology, where techniques based on averaged data and complex and potentially unstable mathematical deconvolution [7,8] are the standard.

[1] EMEA (1999). Note for Guidance on Quality of Modified Release Products: A: Oral Dosage Forms B: Transdermal Dosage Forms Section I (Quality).
[2] Gaynor, C., Dunne, A., and Davis, J. (2009). The effects of averaging on accuracy of IVIVC model predictions. Journal of Pharmaceutical Sciences 98, 3829–3838.
[3] Pinheiro, J. and Bates, D. (2000). Mixed-Effects Models in S and S-PLUS. Statistics and Computing. Springer New York.
[5] Stan Development Team (2018). RStan: the R interface to Stan. R package version 2.17.3.
[6] Gelman, A. (2006). Prior distributions for variance parameters in hierarchical models. Journal of the American Statistical Association 1, 515–534.
[7] Gaynor, C., Dunne, A., and Davis, J. (2008). A Comparison of the Prediction Accuracy of Two IVIVC Modelling Techniques. Journal of Pharmaceutical Sciences 97, 3422 – 3432.
[8] O’Hara, T., Hayes, S., Davis, J., Devane, J., Smart, T. and Dunne, A. (2001). In Vivo–In Vitro Correlation (IVIVC) Modeling Incorporating a Convolution Step. Journal of Pharmacokinetics and Pharmacodynamics 28, 277–298.